This ROS-amplified micelle platform enables targeted therapy for HER2-positive breast cancer brain metastases (BCBM), disrupting the GPX4 ferroptosis defense via dual RSL3 and ROS action to significantly inhibit tumor growth. This evidence concerns the gene ERBB2 and neoplasm.